Skip to main content
. 2020 Jun 10;9(1):1773201. doi: 10.1080/2162402X.2020.1773201

Figure 2.

Figure 2.

(a).PBMC from all seven PC patients were tested for direct cytotoxicity and IFN-γ Elispots responses against MiaPaCa-2 and five phase I patients were tested against NK cell targets K562 for cytotoxicity and IFN-γ Elispots responses; 2b) Shows the highest specific (MiaPaCa-2) and innate (K562) cytotoxic and IFN-γ Elispots responses postIT compared to preIT base line responses; 2 c) IP-10 and IL-8 tested before and after immunotherapy in 7 patients; 2d) PBMC of patient IT20091 obtained at various time points were left unstimulated (background), stimulated with MiaPaCa-2, or K562. Data are expressed as number of IFN-γ Elispots per million PBMC plated at pre-IT; post BATs infusion #1, #3, and #4; 2 and 4 weeks after infusion #3; pre infusion #4; and post boost infusion at 2 and 4 weeks.